替罗非班对急性心肌梗死冠状动脉支架术后冠状动脉再狭窄的影响分析

目的研究替罗非班对急性心肌梗死冠状动脉支架术后冠状动脉再狭窄的影响。方法选取本院2009年1月-2011年1月收治的急性心肌梗死行PCI介入治疗者58例,随机分为观察组和对照组。均于PCI术后给予低分子肝素皮下注射,口服阿司匹林及氯吡格雷治疗。观察组患者在此基础上给予盐酸替罗非班氯化钠注射液静脉滴注24～36h。观察两组治疗前和治疗48h后血小板聚集率及PCI术后6个月冠状动脉再狭窄的发生率。结果观察组接受治疗48h后血小板聚集率显著低于治疗前,且显著低于对照组,差异有统计学意义（P〈0.01）;观察组术后6个月冠状动脉再狭窄发生率为6.9%,显著低于对照组的27.6%,差异有统计学意义（P〈0.05）。结论替罗非班能有效地减低急性心肌梗死PCI术后冠状动脉再狭窄,值得临床推广应用。

The treatmentent effect of Tirofibanon on in-stent restenosis after percutaneous coronary interventions of acute myocardial infarction

Objective To research the effect of Tirofiban on in-stent restenosis after PCI of AMI.Methods Divide 58 patients with AMI accompanied with PCI were into 2 groups.All the patients were treated with LMWH i.h along with aspirin and clopidogrel p.o.The 29 patients in the observation group were treated with Tirofiban i.v for 24-36 h.Record and contrast the AGG after treated for 48 h and the incidence of in-stent restenosis 6 months after PCI.Results The AGG of the observation group was significantly lower than the control group（P0.01）,and the incidence of in-stent restenosis 6 months after PCI was significantly lower than the control group（P0.05）.Conclusion Tirofiban is remarkable effective on preventing in-stent restenosis in patients with AMI accompanied with PCI.